GX-BP2 / Genexine - LARVOL DELTA

Genexine, EPD Bio merger… “Bioprotac new drug development begins in earnest” [Google translation] (Medipana) - "Genexine...announced on the 2nd that it has completed its merger with EPD Biotherapeutics Inc. The company decided to merge with EPD Bio at a board meeting held on June 26th, and signed a merger agreement on July 1st. The merger new stock listing date is scheduled for October 17th...Through this merger, Genexine will acquire EPDeg, a bioPROTAC platform technology that can overcome the limitations of PROTAC...a representative technology in the TPD field, as well as innovative new pipelines and EPD Bio’s key research personnel with many years of industry experience...The pipeline that will enter the clinical stage the fastest is GX-BP1 (SOX2 bioPROTAC) targeting 'SOX2', a cancer-causing transcription factor...Genexine is proceeding with preclinical sample production this year and aims to apply for a domestic phase 1 clinical trial plan (IND) by the end of next year based on the animal testing results...In addition, Genexine is developing GX-BP2..."

M&A • New P1 trial • Atopic Dermatitis • Immunology • Lung Cancer • Oncology • Solid Tumor